JP2010522770A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010522770A5 JP2010522770A5 JP2010501246A JP2010501246A JP2010522770A5 JP 2010522770 A5 JP2010522770 A5 JP 2010522770A5 JP 2010501246 A JP2010501246 A JP 2010501246A JP 2010501246 A JP2010501246 A JP 2010501246A JP 2010522770 A5 JP2010522770 A5 JP 2010522770A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- methyl
- amino
- ethyl
- pyrazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 21
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 18
- 239000003814 drug Substances 0.000 claims 13
- 208000032839 leukemia Diseases 0.000 claims 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 241000124008 Mammalia Species 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 9
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 6
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 6
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 claims 6
- 208000034578 Multiple myelomas Diseases 0.000 claims 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 6
- 206010038389 Renal cancer Diseases 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims 6
- 201000010982 kidney cancer Diseases 0.000 claims 6
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 6
- 201000005202 lung cancer Diseases 0.000 claims 6
- 208000020816 lung neoplasm Diseases 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- -1 2-amino-1-benzylethyl Chemical group 0.000 claims 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 206010003246 arthritis Diseases 0.000 claims 4
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 3
- 201000007815 Bannayan-Riley-Ruvalcaba syndrome Diseases 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000012609 Cowden disease Diseases 0.000 claims 3
- 201000002847 Cowden syndrome Diseases 0.000 claims 3
- 206010014733 Endometrial cancer Diseases 0.000 claims 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 3
- 206010014967 Ependymoma Diseases 0.000 claims 3
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims 3
- 208000036566 Erythroleukaemia Diseases 0.000 claims 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 3
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 claims 3
- 208000032612 Glial tumor Diseases 0.000 claims 3
- 206010018338 Glioma Diseases 0.000 claims 3
- 208000017604 Hodgkin disease Diseases 0.000 claims 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 3
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 claims 3
- 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 claims 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 3
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 claims 3
- 206010027406 Mesothelioma Diseases 0.000 claims 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 3
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 3
- 206010029260 Neuroblastoma Diseases 0.000 claims 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 208000001715 Osteoblastoma Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 208000007452 Plasmacytoma Diseases 0.000 claims 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 3
- 206010061934 Salivary gland cancer Diseases 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 208000000389 T-cell leukemia Diseases 0.000 claims 3
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 3
- 206010042971 T-cell lymphoma Diseases 0.000 claims 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 3
- 206010057644 Testis cancer Diseases 0.000 claims 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 206010047741 Vulval cancer Diseases 0.000 claims 3
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 3
- 208000008383 Wilms tumor Diseases 0.000 claims 3
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 3
- 208000037833 acute lymphoblastic T-cell leukemia Diseases 0.000 claims 3
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 claims 3
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 claims 3
- 201000011143 bone giant cell tumor Diseases 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 201000003444 follicular lymphoma Diseases 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 201000009277 hairy cell leukemia Diseases 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 201000004653 inflammatory breast carcinoma Diseases 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 208000003747 lymphoid leukemia Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 201000008026 nephroblastoma Diseases 0.000 claims 3
- 210000000440 neutrophil Anatomy 0.000 claims 3
- 201000008968 osteosarcoma Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 201000003120 testicular cancer Diseases 0.000 claims 3
- 201000002510 thyroid cancer Diseases 0.000 claims 3
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 201000005102 vulva cancer Diseases 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- ABFYOLRRAFQHQQ-UHFFFAOYSA-N 2-(aminomethyl)-n-[3-(2-methylpyrazol-3-yl)phenyl]-3-phenylpropanamide Chemical compound CN1N=CC=C1C1=CC=CC(NC(=O)C(CN)CC=2C=CC=CC=2)=C1 ABFYOLRRAFQHQQ-UHFFFAOYSA-N 0.000 claims 1
- RMFMLWLATFRKRL-UHFFFAOYSA-N 3-amino-n-[3-chloro-4-(2-methylpyrazol-3-yl)phenyl]-2-phenylpropanamide Chemical compound CN1N=CC=C1C(C(=C1)Cl)=CC=C1NC(=O)C(CN)C1=CC=CC=C1 RMFMLWLATFRKRL-UHFFFAOYSA-N 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- GQISJJJEEUSDGE-UHFFFAOYSA-N n-(1-amino-3-phenylpropan-2-yl)-2-(2-methylpyrazol-3-yl)pyridine-4-carboxamide Chemical compound CN1N=CC=C1C1=CC(C(=O)NC(CN)CC=2C=CC=CC=2)=CC=N1 GQISJJJEEUSDGE-UHFFFAOYSA-N 0.000 claims 1
- HGCDGSLJOMAFRM-UHFFFAOYSA-N n-(1-amino-3-phenylpropan-2-yl)-4-(2-methylpyrazol-3-yl)pyridine-2-carboxamide Chemical compound CN1N=CC=C1C1=CC=NC(C(=O)NC(CN)CC=2C=CC=CC=2)=C1 HGCDGSLJOMAFRM-UHFFFAOYSA-N 0.000 claims 1
- MUVATXQVQPISGR-UHFFFAOYSA-N n-(1-amino-3-phenylpropan-2-yl)-4-(4-chloro-2-methylpyrazol-3-yl)-3-fluorobenzamide Chemical compound CN1N=CC(Cl)=C1C1=CC=C(C(=O)NC(CN)CC=2C=CC=CC=2)C=C1F MUVATXQVQPISGR-UHFFFAOYSA-N 0.000 claims 1
- DLHNYXVQHKMGKF-UHFFFAOYSA-N n-(1-amino-3-phenylpropan-2-yl)-4-chloro-5-(2-methylpyrazol-3-yl)pyridine-2-carboxamide Chemical compound CN1N=CC=C1C1=CN=C(C(=O)NC(CN)CC=2C=CC=CC=2)C=C1Cl DLHNYXVQHKMGKF-UHFFFAOYSA-N 0.000 claims 1
- QPUOHBGHGDEPMW-UHFFFAOYSA-N n-(1-amino-3-phenylpropan-2-yl)-5-(2-methylpyrazol-3-yl)pyridine-2-carboxamide Chemical compound CN1N=CC=C1C1=CC=C(C(=O)NC(CN)CC=2C=CC=CC=2)N=C1 QPUOHBGHGDEPMW-UHFFFAOYSA-N 0.000 claims 1
- JSPQRQRUUQWTNH-UHFFFAOYSA-N n-(1-amino-3-phenylpropan-2-yl)-5-(2-methylpyrazol-3-yl)pyridine-3-carboxamide Chemical compound CN1N=CC=C1C1=CN=CC(C(=O)NC(CN)CC=2C=CC=CC=2)=C1 JSPQRQRUUQWTNH-UHFFFAOYSA-N 0.000 claims 1
- POTWYJVVEVBILJ-UHFFFAOYSA-N n-(1-amino-3-phenylpropan-2-yl)-6-(2-methylpyrazol-3-yl)pyridine-2-carboxamide Chemical compound CN1N=CC=C1C1=CC=CC(C(=O)NC(CN)CC=2C=CC=CC=2)=N1 POTWYJVVEVBILJ-UHFFFAOYSA-N 0.000 claims 1
- ZVLYNYOWUKBHCQ-UHFFFAOYSA-N n-(1-amino-3-phenylpropan-2-yl)-6-(2-methylpyrazol-3-yl)pyridine-3-carboxamide Chemical compound CN1N=CC=C1C1=CC=C(C(=O)NC(CN)CC=2C=CC=CC=2)C=N1 ZVLYNYOWUKBHCQ-UHFFFAOYSA-N 0.000 claims 1
- LOMQBYIMIXOIDD-UHFFFAOYSA-N n-(1-amino-3-phenylpropan-2-yl)-6-chloro-5-(2-methylpyrazol-3-yl)pyridine-2-carboxamide Chemical compound CN1N=CC=C1C1=CC=C(C(=O)NC(CN)CC=2C=CC=CC=2)N=C1Cl LOMQBYIMIXOIDD-UHFFFAOYSA-N 0.000 claims 1
- YADDXIZKYVHMMQ-KRWDZBQOSA-N n-[(2s)-1-amino-3-(3-fluorophenyl)propan-2-yl]-4-(3-methyltriazol-4-yl)benzamide Chemical compound CN1N=NC=C1C1=CC=C(C(=O)N[C@H](CN)CC=2C=C(F)C=CC=2)C=C1 YADDXIZKYVHMMQ-KRWDZBQOSA-N 0.000 claims 1
- GFICRIUQSAJGRZ-HNNXBMFYSA-N n-[(2s)-1-amino-3-[2-(trifluoromethyl)phenyl]propan-2-yl]-3-bromo-4-(2-methylpyrazol-3-yl)benzamide Chemical compound CN1N=CC=C1C1=CC=C(C(=O)N[C@H](CN)CC=2C(=CC=CC=2)C(F)(F)F)C=C1Br GFICRIUQSAJGRZ-HNNXBMFYSA-N 0.000 claims 1
- RMJUJMNPNFPQGP-HNNXBMFYSA-N n-[(2s)-1-amino-3-[2-(trifluoromethyl)phenyl]propan-2-yl]-3-fluoro-4-(2-methylpyrazol-3-yl)benzamide Chemical compound CN1N=CC=C1C1=CC=C(C(=O)N[C@H](CN)CC=2C(=CC=CC=2)C(F)(F)F)C=C1F RMJUJMNPNFPQGP-HNNXBMFYSA-N 0.000 claims 1
- ZFTLBMUSFJFDDC-INIZCTEOSA-N n-[(2s)-1-amino-3-[2-(trifluoromethyl)phenyl]propan-2-yl]-4-(2-methyl-1,2,4-triazol-3-yl)benzamide Chemical compound CN1N=CN=C1C1=CC=C(C(=O)N[C@H](CN)CC=2C(=CC=CC=2)C(F)(F)F)C=C1 ZFTLBMUSFJFDDC-INIZCTEOSA-N 0.000 claims 1
- SMXXLWMICRQSSN-ZDUSSCGKSA-N n-[(2s)-1-amino-3-[2-(trifluoromethyl)phenyl]propan-2-yl]-4-chloro-5-(2-methylpyrazol-3-yl)pyridine-2-carboxamide Chemical compound CN1N=CC=C1C1=CN=C(C(=O)N[C@H](CN)CC=2C(=CC=CC=2)C(F)(F)F)C=C1Cl SMXXLWMICRQSSN-ZDUSSCGKSA-N 0.000 claims 1
- FHNIUCSNOQKWHS-HNNXBMFYSA-N n-[(2s)-1-amino-3-[2-(trifluoromethyl)phenyl]propan-2-yl]-5-(2-methylpyrazol-3-yl)pyridine-2-carboxamide Chemical compound CN1N=CC=C1C1=CC=C(C(=O)N[C@H](CN)CC=2C(=CC=CC=2)C(F)(F)F)N=C1 FHNIUCSNOQKWHS-HNNXBMFYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90874107P | 2007-03-29 | 2007-03-29 | |
| PCT/US2008/058603 WO2008121786A1 (en) | 2007-03-29 | 2008-03-28 | Inhibitors of akt activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010522770A JP2010522770A (ja) | 2010-07-08 |
| JP2010522770A5 true JP2010522770A5 (enExample) | 2011-05-12 |
Family
ID=39808679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010501246A Withdrawn JP2010522770A (ja) | 2007-03-29 | 2008-03-28 | Ａｋｔ活性の阻害物質 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8338434B2 (enExample) |
| EP (1) | EP2134175A4 (enExample) |
| JP (1) | JP2010522770A (enExample) |
| WO (1) | WO2008121786A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| MX2011004570A (es) * | 2008-10-31 | 2011-06-17 | Merck Sharp & Dohme | Antagonistas del receptor p2x3 para el tratamiento del dolor. |
| CN102405047B (zh) | 2009-01-30 | 2014-07-09 | 葛兰素史密斯克莱有限责任公司 | 结晶型的n-{(1s)-2-氨基-1-[(3-氟苯基)甲基]乙基}-5-氯-4-(4-氯-1-甲基-1h-吡唑-5-基)-2-噻吩甲酰胺盐酸盐 |
| WO2010094009A2 (en) * | 2009-02-13 | 2010-08-19 | Children's Hospital Medical Center | Methods and compositions for the treatment of ras associated disorders |
| US20130225524A1 (en) * | 2010-11-05 | 2013-08-29 | Deping Chai | Chemical Compounds |
| WO2013056015A1 (en) * | 2011-10-14 | 2013-04-18 | Incyte Corporation | Isoindolinone and pyrrolopyridinone derivatives as akt inhibitors |
| WO2013096151A1 (en) * | 2011-12-22 | 2013-06-27 | Glaxosmithkline Llc | Chemical compounds |
| WO2013096153A1 (en) * | 2011-12-22 | 2013-06-27 | Glaxosmithkline Llc | Chemical compounds |
| TW201332989A (zh) * | 2011-12-23 | 2013-08-16 | Millennium Pharm Inc | 雜芳基化合物及其用途 |
| CN112472699A (zh) | 2013-07-26 | 2021-03-12 | 种族肿瘤学公司 | 改善比生群及衍生物的治疗益处的组合方法 |
| CN112888440A (zh) | 2018-10-16 | 2021-06-01 | 豪夫迈·罗氏有限公司 | Akt抑制剂在眼科中的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1423380B1 (en) * | 2001-08-03 | 2010-12-15 | Vertex Pharmaceuticals Incorporated | Pyrazole-derived kinase inhibitors and uses thereof |
| TW200306819A (en) * | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| GB0215844D0 (en) * | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| US20060270643A1 (en) * | 2002-10-31 | 2006-11-30 | Chawnshang Chang | Hyfroxyflutamide induced pathways related to androgen receptor negative prostate cancer cells |
| EP2385041B1 (en) * | 2003-05-01 | 2013-09-18 | Bristol-Myers Squibb Company | Pyrazole-amine compounds useful as kinase inhibitors |
| US8211919B2 (en) * | 2005-09-02 | 2012-07-03 | Astellas Pharma Inc. | Amide derivatives as rock inhibitors |
-
2008
- 2008-03-28 EP EP08744560A patent/EP2134175A4/en not_active Withdrawn
- 2008-03-28 JP JP2010501246A patent/JP2010522770A/ja not_active Withdrawn
- 2008-03-28 WO PCT/US2008/058603 patent/WO2008121786A1/en not_active Ceased
- 2008-03-28 US US12/593,415 patent/US8338434B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010522770A5 (enExample) | ||
| JP2022185107A5 (enExample) | ||
| JP2010518110A5 (enExample) | ||
| JP2017508763A5 (enExample) | ||
| JP2019531274A5 (enExample) | ||
| JP2019514938A5 (enExample) | ||
| JP2019521109A5 (enExample) | ||
| JP2018138577A5 (enExample) | ||
| JP2014526510A5 (enExample) | ||
| RU2018146946A (ru) | Химические соединения | |
| JP2020506946A5 (enExample) | ||
| JP2016513660A5 (enExample) | ||
| JP2018507877A5 (enExample) | ||
| JP2014508811A5 (enExample) | ||
| JP2016539180A5 (enExample) | ||
| JP2013507350A5 (enExample) | ||
| RU2016141088A (ru) | 5-замещённые индазол-3-карбоксамиды и их получение и применение | |
| JP2020503297A5 (enExample) | ||
| JP2015503529A5 (enExample) | ||
| JP2013525458A5 (enExample) | ||
| IL291590B2 (en) | Novel substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof | |
| JP2022511477A5 (enExample) | ||
| JP2021529814A5 (enExample) | ||
| JP2017530185A5 (enExample) | ||
| WO2009107391A1 (ja) | ６員芳香環含有化合物 |